←Back to Expert Scholars
Translational Medicine / 转化医学AML Novel Targets, Immunotherapy
Naval Daver
MD
🏢MD Anderson Cancer Center🌐USA
Director, Leukemia Research Alliance Program
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Naval Daver leads the Leukemia Research Alliance at MD Anderson and has run numerous novel AML trials including CD47, menin, and checkpoint inhibitors in AML. He has pioneered AML immunotherapy combinations. His work explores next-generation AML targets.
Share:
🧪Research Fields 研究领域
AML immunotherapy
magrolimab CD47
AML novel combinations
venetoclax combinations
menin inhibitors
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Naval Daver 的研究动态
Follow Naval Daver's research updates
留下邮箱，当我们发布与 Naval Daver（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment